Commission signs joint procurement contract for up to 24 million doses of RSV vaccine ahead of the 2026-2027 winter season

From the official press release: 

"The European Commission has signed, on the request of 6 countries, a joint procurement framework contract with Moderna to access up to 24 million doses of the mRNA-based RSV (Respiratory Syncytial Virus) vaccine mRESVIA®, with no minimum number of doses to be bought. This vaccine protects against diseases of the lungs, such as bronchitis and pneumonia, caused by RSV in adults. The contract will run for a period of up to four years.

...

As of July 2026, 39 countries have signed the Joint Procurement Agreement, a mechanism at EU level to jointly procure medical countermeasures on a voluntary and flexible basis. This mechanism contributes to EU-level preparedness for public health crises or pandemics.

Hadja Lahbib, Commissioner for Equality, Preparedness and Crisis Management, said: “With today's joint procurement for a RSV vaccine, we are helping Member States to enhance their preparedness against this serious virus before the upcoming winter season. This will protect the most vulnerable and reduce the pressure that respiratory infections place on our hospitals during the winter months. Being prepared today means saving lives when the next peak season arrives.”